Time for more optimism in metastatic breast cancer?

Cancer Treatment Reviews

Volumn 40, Issue 2, 2014, Pages 220-228

  Senkus, Elzbieta ^a   Cardoso, Fatima ^b   Pagani, Olivia ^c  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Champalimaud Cancer Center   (Portugal)

^c OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

ABC guidelines; Chemotherapy; Endocrine therapy; Intrinsic subtypes; Metastatic breast cancer; Targeted therapy

Indexed keywords

AFATINIB; ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GONADORELIN AGONIST; LAPATINIB; LETROZOLE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; NERATINIB; OLAPARIB; PACLITAXEL; PLATINUM; PROTEIN KINASE; PROTEIN KINASE B; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; VASCULOTROPIN;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BRAIN METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL PROLIFERATION; DRUG COST; HUMAN; MOLECULAR INTERACTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STEREOTACTIC RADIOSURGERY; TIME TO TREATMENT; TOMOTHERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER;

ABC GUIDELINES; CHEMOTHERAPY; ENDOCRINE THERAPY; INTRINSIC SUBTYPES; METASTATIC BREAST CANCER; TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; MOLECULAR TARGETED THERAPY; QUALITY OF LIFE; RECEPTOR, ERBB-2; SURVIVAL RATE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888299651     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.09.015     Document Type: Review

References (140)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Dawood S., Broglio K., Buzdar A.U., et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010, 28:92-98.
4. Kennecke H., Yerushalmi R., Woods R., et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277.
5. Smid M., Wang Y., Zhang Y., et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68:3108-3114.
6. Lin N.U., Claus E., Sohl J., et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008, 113:2638-2645.
7. Metzger-Filho O., Sun Z., Viale G., et al. Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 2013, published, online July 29, 2013.
8. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-2746.
9. Tischkowitz M., Brunet J.-S., Begin L., et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007, 7:134-144.
10. Kennecke H.F., Olivotto I.A., Speers C., et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5years of tamoxifen. Ann Oncol 2007, 18:45-51.
11. Fan C., Prat A., Parker J.S., et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics 2011, 4:3.
12. Yang X.R., Chang-Claude J., Goode E.L., et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies. J Natl Cancer Inst 2011, 103:250-263.
13. Blows F.M., Driver K.E., Schmidt M.K., et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010, 7:e1000279.
14. Cheang M.C.U., Chia S.K., Voduc D., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750.
15. Cardoso F., Bischoff J., Brain E., et al. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 2013, 39:457-465.
16. Gibson L., Dawson C., Lawrence D., Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review). The Cochrane Collaboration 2009, John Wiley & Sons Ltd.
17. Croxtall J.D., McKeage K. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs 2011, 71:363-380.
18. Robertson J.F.R., Lindemann J.P.O., Llombart-Cussac A., et al. Fulvestrant 500mg versus anastrozole 1mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 2012, 136:503-511.
19. Di Leo A., Jerusalem G., Petruzelka L., et al. Results of the CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28:4594-4600.
20. Johnston S., Kilburn L.S., Ellis P., et al. Fulvestrant alone or with concomitant anastrozole vs. exemestane following progression on non-steroidal aromatase inhibitor-first results of the Sofea trial (cruke/03/021 and cruk/09/007) (isrctn44195747). Eur J Cancer 2012, 48(Suppl. 3):S2. abstract LBA2.
21. Bergh J., Jönsson P.E., Lidbrink E.K., et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012, 30:1919-1925.
22. Mehta R.S., Barlow W.E., Albain K.S., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012, 367:435-444.
23. Bachelot T., Bourgier C., Cropet C., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012, 30:2718-2724.
24. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
25. Wolff A.C., Lazar A.A., Bondarenko I., et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013, 31:195-202.
26. Klijn J.G., Blamey R.W., Boccardo F., et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001, 19:343-353.
27. Celio L., Martinetti A., Ferrari L., et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 1999, 19:2261-2268.
28. Carlson R.W., Theriault R., Schurman C.M., et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 2010, 28:3917-3921.
29. Park I.H., Ro J., Lee K.S., et al. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol 2010, 28:2705-2711.
30. Bartsch R., Bago-Horvath Z., Berghoff A., et al. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer 2012, 48:1932-1938.
31. Young O.E., Renshaw L., Macaskill E.J., et al. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 2008, 44:391-399.
32. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002, 2:101-112.
33. Johnston S. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16:1979-1987.
34. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
35. Finn R.S., Crown J.P., Boer K., et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). Ann Oncol 2012, 23(Suppl. 2):243-245.
36. Irvin W.J., Carey L.A. What is triple-negative breast cancer?. Eur J Cancer 2008, 44:2799-2805.
37. Montagna E., Maisonneuve P., Rotmensz N., et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer 2013, 13:31-39.
38. Dent R., Hanna W.M., Trudeau M., et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009, 115:423-428.
39. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8:235-244.
40. Gluz O., Liedtke C., Gottschalk N., et al. Triple-negative breast cancer - current status and future directions. Ann Oncol 2009, 20:1913-1927.
41. Kassam F., Enright K., Dent R., et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009, 9:29-33.
42. Isakoff S.J. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010, 16:53-61.
43. Oakman C., Moretti E., Di Leo A. Re-searching anthracycline therapy. Breast Cancer Res Treat 2010, 123:171-175.
44. Tutt A., Robson M., Garber J.E., et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
45. O'Shaughnessy J., Osborne C., Pippen J.E., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011, 364:205-214.
46. O'Shaughnessy J., Schwartzberg L.S., Danso M.A., et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011, 29(Suppl.). abstr 1007.
47. Fong P.C., Boss D.S., Yap T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
48. Gelmon K.A., Tischkowitz M., Mackay H., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12:852-861.
49. Lehmann B.D., Bauer J.A., Chen X., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767.
50. Hudis C.A. Trastuzumab mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
51. Goel S., Chirgwin J., Francis P., et al. Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research. Breast 2011, 20:101-110.
52. Andersson M., Lidbrink E., Bjerre K., et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 2011, 29:264-271.
53. Burstein H.J., Keshaviah A., Baron A.D., et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007, 110:965-972.
54. Fabi A., Metro G., Ferretti G., et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? a mono-institutional experience and systematic review of observational studies. Breast 2008, 17:499-505.
55. Menard S. Observational demetra study: survival of metastatic breast carcinoma patients after treatment with trastuzumab. J Clin Oncol 2008, 26. abstr 1062.
56. Brufsky A.M., Mayer M., Rugo H.S., et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011, 17:4834-4843.
57. Extra J.M., Antoine E.C., Vincent-Salomon A., et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational hermine study. Oncologist 2010, 15:799-809.
58. von Minckwitz G.,Bois A., Schmidt M., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009, 27:1999-2006.
59. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008, 112:533-543.
60. Pestalozzi B.C., Zahrieh D., Price K.N., et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG). Ann Oncol 2006, 17:935-944.
61. Gabos Z., Sinha R., Hanson J., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 2006, 24:5658-5663.
62. Lin N.U., Carey L.A., Liu M.C., et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008, 26:1993-1999.
63. Lin N.U., Dieras V., Paul D., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15:1452-1459.
64. Lin N.U., Eierman W., Greil R., et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011, 105:613-620.
65. Bachelot T., Romieu G., Campone M., et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013, 14:64-71.
66. Pivot X., Semiglazov V., Zurawski B., et al. CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) vs. trastuzumab plus capecitabine (TC). Ann Oncol 2012, 23(Suppl. 9):ixe5.
67. Di Leo A., Gomez H.L., Aziz Z., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as firstline treatment for metastatic breast cancer. J Clin Oncol 2008, 26:5544-5552.
68. Gelmon K.A., Boyle F., Kaufman B., et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 2012, 30(Suppl.). abstr LBA671.
69. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
70. Baselga J., Cortés J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
71. Swain S.M., Kim S.-B., Cortes J., et al. Confirmatory overall survival (OS) analysis of cleopatra: a randomized, double-blind, placebo-controlled phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with her2-positive first-line (1L) metastatic breast cancer (MBC). Cancer Res 2012, 72(24 Suppl.):64S.
72. Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
73. Konecny G., Pauletti G., Pegram M., et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor positive primary breast cancer. J Natl Cancer Inst 2003, 95:142-153.
74. De Laurentiis M., Arpino G., Massarelli E., et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005, 11:4741-4748.
75. Osborne C.K., Shou J., Massarweh S., et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005, 11(Suppl.):865s-870s.
76. Jones A. Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?. Ann Oncol 2003, 14:1697-1704.
77. Johnston S. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 2005, 11(Suppl.):889s-899s.
78. Kaufman B., Mackey J.R., Clemens M.R., et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
79. Schwartzberg L.S., Franco S.X., Florance A., et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010, 15:122-129.
80. Huober J., Fasching P.A., Barsoum M., et al. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012, 21:27-33.
81. Cardoso F., Costa A., Norton L., et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012, 21:242-252.
82. Tolaney S.M., Krop I.E. Mechanisms of trastuzumab resistance in breast cancer. Anticancer Agents Med Chem 2009, 9:348-355.
83. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007, 18:977-984.
84. Burstein H.J., Sun Y., Dirix L.Y., et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 28:1301-1307.
85. Swaby R., Blackwell K., Jiang Z., et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. J Clin Oncol 2009, 27(15 Suppl.):1004.
86. Awada A., Dirix L., Manso Sanchez L., et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol 2013, 24:109-116.
87. Lin N.U., Winer E.P., Wheatley D., et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012, 133:1057-1065.
88. Martin M., Bonneterre J., Geyer C.E., et al. A phase 2, randomized, open-label, study of neratinib (HKI-272) vs. lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2{thorn} locally advanced or metastatic breast cancer. Cancer Res 2011, 71(24 Suppl.). abstract S5e7.
89. Robertson J.F., Steger G.G., Neven P., et al. Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol 2010, 21:1246-1253.
90. Hamberg P., Bos M.M., Braun H.J., et al. Dutch breast cancer trialists' group (BOOG). randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2(+) metastatic breast cancer: HERTAX trial. Clin Breast Cancer 2011, 11:103-113.
91. Inoue K., Nakagami K., Mizutani M., et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 trial group. Breast Cancer Res Treat 2010, 119:127-136.
92. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
93. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
94. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
95. Robert N.J., Diéras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
96. Lee J.B., Woo O.H., Park K.H., et al. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs 2009, 29:182-188.
97. Valachis A., Polyzos N.P., Patsopoulos N.A., et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010, 122:1-7.
98. Cuppone F., Bria E., Vaccaro V., et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials. J Exp Clin Cancer Res 2011, 30:54-62.
99. Wagner A.D., Thomssen C., Haerting J., Unverzagt S. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev 2012, 7:CD008941.
100. Nielsen D.L., Andersson M., Lykkegaard Andersen J., Kamby C. Antiangiogenic therapy for breast cancer. Breast Cancer Res 2010, 12:209-224.
101. Klijn J.G., Berns P.M., Schmitz P.I., et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992, 13:3-17.
102. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
103. Baselga J., Stemmer S., Pego A., et al. Cetuximab+cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: results of the randomized phase II BALI-1 trial. Cancer Res 2010, 70(24 Suppl. 2). abstr. PD01-01.
104. Cardoso F., Bedard P.L., Winer E.P., et al. International guidelines for management of metastatic breast cancer: combination vs. sequential single-agent chemotherapy. J Natl Cancer Inst 2009, 101:1174-1181.
105. Colleoni M., Rocca A., Sandri M.T., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13:73-80.
106. Cortes J., O'Shaughnessy J., Loesch D., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011, 377:914-923.
107. Cortes J., Vidal M. Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat 2012, 133:821-830.
108. Le Scodan S.R., Stevens D., Brain E., et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol 2009, 27:1375-1381.
109. Ruiterkamp J., Voogd A.C., Bosscha K., Tjan-Heijnen V.C., Ernst M.F. Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat 2010, 120:9-16.
110. Bafford A.C., Burstein H.J., Barkley C.R., et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat 2009, 115:7-12.
111. Morgan S.C., Parker C.C. Local treatment of metastatic cancer-killing the seed or disturbing the soil?. Nat Rev Clin Oncol 2011, 8:504-506.
112. Soran A., Ozbas S., Kelsey S.F., Gulluoglu B.M. Randomized trial comparing locoregional resection of primary tumor with no surgery in stage IV breast cancer at the presentation (Protocol MF07-01): a study of Turkish federation of the national societies for breast diseases. Breast J 2009, 15:399-403.
113. Sparano J.A., Pisano E.D., White J.R., et al. Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy. Breast Cancer Res Treat 2010, 120:273-284.
114. Weichselbaum R.R., Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011, 8:378-382.
115. Pockaj B.A., Wasif N., Dueck A.C., et al. Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look?. Ann Surg Oncol 2010, 17:2419-2426.
116. Bergenfeldt M., Jensen B.V., Skjoldbye B., Nielsen D. Liver resection and local ablation of breast cancer liver metastases - a systematic review. Eur J Surg Oncol 2011, 37:549-557.
117. Howlader M., Heaton N., Rela M. Resection of liver metastases from breast cancer: towards a management guideline. Int J Surg 2011, 9:285-291.
118. Pagani O., Senkus E., Wood W., et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?. J Natl Cancer Inst 2010, 102:456-463.
119. Orgera G., Monfardini L., Della V.P., et al. High-intensity focused ultrasound (HIFU) in patients with solid malignancies: evaluation of feasibility, local tumour response and clinical results. Radiol Med 2011, 116:734-748.
120. Coldwell D.M., Kennedy A.S., Nutting C.W. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 2007, 69:800-804.
121. Vogl T.J., Naguib N.N., Nour-Eldin N.E., et al. Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer. Am J Roentgenol 2011, 196:W66-W72.
122. Cahill K.S., Chi J.H., Day A.L., Claus E.B. Trends in survival after surgery for breast cancer metastatic to the brain and spinal column in medicare patients: a population-based analysis. Neurosurgery 2011, 68:705-713.
123. Kondziolka D., Kano H., Harrison G.L., et al. Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Clinical article. J Neurosurg 2011, 114:792-800.
124. Chargari C., Campana F., Pierga J.Y., et al. Whole-brain radiation therapy in breast cancer patients with brain metastases. Nat Rev Clin Oncol 2010, 7:632-640.
125. Mehta M.P., Paleologos N.A., Mikkelsen T., et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:71-83.
126. Chao S.T., Koyfman S.A., Woody N., et al. Recursive partitioning analysis index is predictive for overall survival in patients undergoing spine stereotactic body radiation therapy for spinal metastases. Int J Radiat Oncol Biol Phys 2012, 82:1738-1743.
127. Cheung G., Chow E., Holden L., et al. Percutaneous vertebroplasty in patients with intractable pain from osteoporotic or metastatic fractures: a prospective study using quality-of-life assessment. Can Assoc Radiol J 2006, 57:13-21.
128. Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
129. Body J.J. New developments for treatment and prevention of bone metastases. Curr Opin Oncol 2011, 23:338-342.
130. Van Poznak C.H., Temin S., Yee G.C., et al. American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011, 29:1221-1227.
131. Clezardin P. Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res 2011, 13:207-216.
132. Verma S., McLeod D., Batist G., et al. In the end what matters most? a review of clinical endpoints in advanced breast cancer. Oncologist 2011, 16:25-35.
133. Broglio K.R., Berry D.A. Detecting an overall survival benefit that is derived from progression to free survival. J Natl Cancer Inst 2009, 101:1642-1649.
134. Hayashi N., Nakamura S., Tokuda Y., et al. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol 2012, 17:96-104.
135. Rosen L.S., Ashurst H.L., Chap L. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 2010, 15:216-235.
136. Alvarez R.H., Valero V., Hortobagyi G.N. Emerging targeted therapies for breast cancer. J Clin Oncol 2010, 28:3366-3379.
137. Garrett J.T., Arteaga C.L. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 2011, 11:793-800.
138. El Saghir N.S., Adebamowo C.A., Anderson B.O., et al. Breast cancer management in low resource countries (LRCs): consensus statement from the breast health global initiative. Breast 2011, 20(Suppl. 2):S3-11.
139. Hoffman J.M., Shah N.D., Vermeulen L.C., et al. Projecting future drug expenditures-2008. Am J Health Syst Pharm 2008, 65:234-253.
140. Blank P.R., Dedes K.J., Szucs T.D. Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. Pharmacoeconomics 2010, 28:629-647.